Safety and efficacy of intravenous lacosamide for adjunctive treatment of refractory status epilepticus: A comparative cohort study

CNS Drugs

Volumn 27, Issue 4, 2013, Pages 321-329

  Sutter, Raoul ^a,b   Marsch, Stephan ^a   Rüegg, Stephan ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HARKOSERIDE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CRITICALLY ILL PATIENT; DEATH; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ELECTROENCEPHALOGRAM; EPILEPTIC STATE; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT OUTCOME;

ACETAMIDES; ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANTICONVULSANTS; COHORT STUDIES; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATUS EPILEPTICUS; TERTIARY CARE CENTERS; TREATMENT OUTCOME; VIDEO RECORDING;

EID: 84878264159     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0049-y     Document Type: Article

References (50)

1. Knake S, Rosenow F, Vescovi M, et al. Incidence of status epilepticus in adults in Germany: A prospective, population-based study. Epilepsia. 2001;42(6):714-8.
2. Hesdorffer DC, Logroscino G, Cascino G, et al. Incidence of status epilepticus in Rochester, Minnesota, 1965-1984. Neurology. 1998;50(3):735-41.
3. Leppert D, Stöckli HR, Fuhr P. Richtlinien zur Behandlung des Status epilepticus. Schweiz Ärztetzeitung. 2005;86:1-14.
4. Meierkord H, Boon P, Engelsen B, et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol. 2010;17(3):348-55.
5. Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: A critical review of available therapies and a clinical treatment protocol. Brain. 2011;134(Pt 10):2802-18.
6. Rossetti AO, Lowenstein DH. Management of refractory status epilepticus in adults: Still more questions than answers. Lancet Neurol. 2011;10(10):922-30.
7. Holtkamp M, Masuhr F, Harms L, et al. The management of refractory generalised convulsive and complex partial status epilepticus in three European countries: A survey among epileptologists and critical care neurologists. J Neurol Neurosurg Psychiatry. 2003;74(8):1095-9.
8. Kaplan PW. Nonconvulsive status epilepticus. Neurology. 2003;61(8):1035-6.
9. Cooper AD, Britton JW, Rabinstein AA. Functional and cognitive outcome in prolonged refractory status epilepticus. Arch Neurol. 2009;66(12):1505-9.
10. Towne AR, Pellock JM, Ko D, et al. Determinants of mortality in status epilepticus. Epilepsia. 1994;35(1):27-34.
11. Lowenstein DH, Alldredge BK. Status epilepticus. N Engl J Med. 1998;338(14):970-6.
12. Holtkamp M, Othman J, Buchheim K, et al. A "malignant" variant of status epilepticus. Arch Neurol. 2005;62(9):1428-31.
13. Rossetti AO, Logroscino G, Bromfield EB. Refractory status epilepticus: Effect of treatment aggressiveness on prognosis. Arch Neurol. 2005;62(11):1698-703.
14. Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: A prospective observational study. Epilepsia. 2010;51(2):251-6.
15. Bausell R, Svoronos A, Lennihan L, et al. Recovery after severe refractory status epilepticus and 4 months of coma. Neurology. 2011;77(15):1494-5.
16. + current and slow cumulative spike adaptation in mouse and guinea-pig neocortical neurones in slices. J Physiol. 1996;493(Pt 1):83-97.
17. Mickus T, Jung H, Spruston N. Properties of slow, cumulative sodium channel inactivation in rat hippocampal CA1 pyramidal neurons. Biophys J. 1999;76(2):846-60.
18. Beyreuther BK, Freitag J, Heers C, et al. Lacosamide: A review of preclinical properties. CNS Drug Rev. 2007;13(1):21-42.
19. Yoshimura T, Kawano Y, Arimura N, et al. GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell. 2005;120(1):137-49.
20. Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007;48(7):1308-17.
21. Biton V, Rosenfeld WE, Whitesides J, et al. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia. 2008;49(3):418-24.
22. Krause LU, Brodowski KO, Kellinghaus C. Atrioventricular block following lacosamide intoxication. Epilepsy Behav. 2011;20(4):725-7.
23. Nizam A, Mylavarapu K, Thomas D, et al. Lacosamide-induced second-degree atrioventricular block in a patient with partial epilepsy. Epilepsia. 2011;52(10):e153-5.
24. Degiorgio CM. Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures. Epilepsy Behav. 2010;18(3):322-4.
25. Kellinghaus C, Berning S, Immisch I, et al. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand. 2011;123(2):137-41.
26. Chen LL, Haneef Z, Dorsch A, et al. Successful treatment of refractory simple motor status epilepticus with lacosamide and levetiracetam. Seizure. 2011;20(3):263-5.
27. Shiloh-Malawsky Y, Fan Z, Greenwood R, et al. Successful treatment of childhood prolonged refractory status epilepticus with lacosamide. Seizure. 2011;20(7):586-8.
28. Mnatsakanyan L, Chung JM, Tsimerinov EI, et al. Intravenous lacosamide in refractory nonconvulsive status epilepticus. Seizure. 2012;21:198-201.
29. Rantsch K, Walter U, Wittstock M, et al. Efficacy of intravenous lacosamide in refractory nonconvulsive status epilepticus and simple partial status epilepticus. Seizure. 2011;20(7):529-32.
30. Fernandez EM, Franck AJ. Lacosamide for the treatment of refractory status epilepticus. Ann Pharmacother. 2011;45(11):1445-9.
31. Rossetti AO, Logroscino G, Liaudet L, et al. Status epilepticus: An independent outcome predictor after cerebral anoxia. Neurology. 2007;69(3):255-60.
32. Wijdicks EF, Parisi JE, Sharbrough FW. Prognostic value of myoclonus status in comatose survivors of cardiac arrest. Ann Neurol. 1994;35(2):239-43.
33. Young GB, Gilbert JJ, Zochodne DW. The significance of myoclonic status epilepticus in postanoxic coma. Neurology. 1990;40(12):1843-8.
34. Hui AC, Cheng C, Lam A, et al. Prognosis following postanoxic myoclonus status epilepticus. Eur Neurol. 2005;54(1):10-3.
35. Rüegg S, Naegelin Y, Hardmeier M, et al. Intravenous levetiracetam: Treatment experience with the first 50 critically ill patients. Epilepsy Behav. 2008;12(3):477-80.
36. Young GB, Jordan KG, Doig GS. An assessment of nonconvulsive seizures in the intensive care unit using continuous EEG monitoring: An investigation of variables associated with mortality. Neurology. 1996;47(1):83-9.
37. Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia. 1999;40(1):120-2.
38. Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3-23.
39. Commission on Epidemiology and Prognosis ILAE. Guidelines for epidemiologic studies on epilepsy. Epilepsia. 1993;34(4):592-6.
40. Rossetti AO, Logroscino G, Bromfield EB. A clinical score for prognosis of status epilepticus in adults. Neurology. 2006;66(11):1736-8.
41. Rossetti AO, Logroscino G, Milligan TA, et al. Status Epilepticus Severity Score (STESS): A tool to orient early treatment strategy. J Neurol. 2008;255(10):1561-6.
42. Hofler J, Unterberger I, Dobesberger J, et al. Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia. 2011;52(10):e148-52.
43. Zangaladze A, Skidmore C. Lacosamide use in refractory idiopathic primary generalized epilepsy. Epilepsy Behav. 2012;23(1):79-80.
44. Holtkamp M, Othman J, Buchheim K, et al. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry. 2005;76(4):534-9.
45. Drislane FW, Blum AS, Lopez MR, et al. Duration of refractory status epilepticus and outcome: Loss of prognostic utility after several hours. Epilepsia. 2009;50(6):1566-71.
46. Sutter R, Fuhr P, Grize L, et al. Continuous video-EEG monitoring increases detection rate of nonconvulsive status epilepticus in the ICU. Epilepsia. 2011;52(3):453-7.
47. Logroscino G, Hesdorffer DC, Cascino G, et al. Short-term mortality after a first episode of status epilepticus. Epilepsia. 1997;38(12):1344-9.
48. Claassen J, Lokin JK, Fitzsimmons BFM, et al. Predictors of functional disability and mortality after status epilepticus. Neurology. 2002;58(1):139-42.
49. Sutter R, Marsch S, Fuhr P, Rüegg S. Mortality and recovery from refractory status epileticus in the ICU: A 7-year observational study. Epilepsia. 2013;54(3):502-11.
50. Towne AR. Epidemiology and outcomes of status epilepticus in the elderly. Int Rev Neurobiol. 2007;81:111-27.